# CHemoImmunotherapy With Early Central Nervous System (CNS) Prophylaxis

> **NCT01325194** · PHASE2 · COMPLETED · sponsor: **Nordic Lymphoma Group** · enrollment: 143 (actual)

## Conditions studied

- Primary Disease

## Interventions

- **DRUG:** liposomal cytarabine

## Key facts

- **NCT ID:** NCT01325194
- **Lead sponsor:** Nordic Lymphoma Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03
- **Primary completion:** 2018-11
- **Final completion:** 2019-12-31
- **Target enrollment:** 143 (ACTUAL)
- **Last updated:** 2020-03-03

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01325194

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01325194, "CHemoImmunotherapy With Early Central Nervous System (CNS) Prophylaxis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01325194. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*